NASDAQ : ENGN
enGene Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · Canada
Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 40.39M | 28.68M | 23.98M | 9.60M | 3.96M | 3.41M |
| Research & Development | 96.26M | 94.48M | 38.31M | 16.46M | 15.47M | 12.46M |
| Operating Expenses | 136.65M | 123.17M | 62.30M | 26.06M | 19.43M | 15.87M |
| Operating Income | -136.65M | -123.17M | -62.30M | -26.06M | -19.43M | -15.87M |
| Interest Expense | -3.07M | -2.99M | -2.80M | -4.95M | -1.42M | -5.02M |
| Interest & Investment Income | 9.78M | 9.43M | 10.41M | 1.12M | 129.00K | 25.00K |
| Currency Exchange Gain (Loss) | -430.00K | -569.00K | -113.00K | -129.00K | -700.00K | -100.00K |
| Other Non Operating Income (Expenses) | -10.57M | -3.02M | -4.20M | |||
| EBT Excluding Unusual Items | -130.37M | -117.30M | -54.80M | -40.60M | -24.44M | -25.17M |
| Other Unusual Items | -488.00K | -366.00K | -59.30M | 1.73M | ||
| Pretax Income | -130.86M | -117.30M | -55.16M | -99.90M | -24.44M | -23.44M |
| Income Tax Expense | -497.00K | -19.00K | 17.00K | 22.00K | ||
| Net Income | -130.36M | -117.30M | -55.14M | -99.92M | -24.46M | -23.44M |
| Preferred Dividends & Other Adjustments | 4.82M | 4.56M | -1.19M | |||
| Net Income to Common | -130.36M | -117.30M | -55.14M | -104.74M | -29.02M | -22.25M |
| Shares Outstanding (Basic) | 64.52M | 51.12M | 37.78M | 692.61K | 655.15K | 3.56M |
| Shares Outstanding (Diluted) | 64.52M | 51.12M | 37.78M | 692.61K | 655.15K | 3.56M |
| EPS (Basic) | -2.02 | -2.29 | -1.46 | -151.22 | -44.30 | -6.25 |
| EPS (Diluted) | -2.02 | -2.29 | -1.46 | -151.22 | -44.30 | -6.25 |
| Free Cash Flow | -104.00M | -100.72M | -49.21M | -25.06M | -17.75M | -16.23M |
| Free Cash Flow Per Share | -1.61 | -1.97 | -1.30 | -36.18 | -27.09 | -4.56 |
| EBITDA | -135.93M | -122.66M | -61.97M | -25.89M | -19.19M | -15.60M |
| D&A For EBITDA | 718.00K | 509.00K | 323.00K | 175.00K | 238.00K | 272.00K |
| EBIT | -136.65M | -123.17M | -62.30M | -26.06M | -19.43M | -15.87M |
Balance sheet
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 41.02M | 50.15M | 173.00M | 81.52M | 20.43M | 11.02M |
| Short-Term Investments | 225.29M | 143.58M | 65.33M | |||
| Cash & Short-Term Investments | 266.32M | 193.74M | 238.33M | 81.52M | 20.43M | 11.02M |
| Other Receivables | 2.88M | 2.23M | 1.03M | 2.34M | 1.34M | 1.62M |
| Receivables | 2.88M | 2.23M | 1.03M | 2.34M | 1.34M | 1.62M |
| Prepaid Expenses | 8.63M | 5.35M | 7.93M | 1.50M | 739.00K | 797.00K |
| Other Current Assets | 79.00K | 79.00K | 72.00K | 76.00K | 74.00K | 81.00K |
| Total Current Assets | 277.90M | 201.39M | 247.36M | 85.44M | 22.58M | 13.52M |
| Property, Plant & Equipment | 9.03M | 10.19M | 2.91M | 589.00K | 387.00K | 571.00K |
| Long-Term Investments | 8.52M | 59.53M | ||||
| Other Long-Term Assets | 1.39M | 1.36M | 1.37M | 930.00K | 939.00K | 939.00K |
| Total Assets | 288.32M | 221.47M | 311.17M | 86.96M | 23.91M | 15.03M |
| Accounts Payable | 2.54M | 6.69M | 1.41M | 1.16M | 723.00K | 1.00M |
| Accrued Expenses | 21.55M | 14.68M | 11.90M | 3.39M | 3.09M | 1.08M |
| Current Portion of Long-Term Debt | 199.00K | 8.00M | 699.00K | 562.00K | 1.26M | 1.05M |
| Current Portion of Leases | 2.25M | 2.01M | 423.00K | 61.00K | ||
| Current Income Taxes Payable | 19.00K | 39.00K | 22.00K | |||
| Other Current Liabilities | 665.00K | 577.00K | 225.00K | 113.00K | 21.00K | |
| Total Current Liabilities | 27.21M | 31.98M | 14.66M | 5.26M | 5.10M | 3.22M |
| Long-Term Debt | 25.16M | 15.32M | 22.47M | 9.22M | 27.05M | 2.44M |
| Long-Term Leases | 5.67M | 6.46M | 1.43M | |||
| Other Long-Term Liabilities | 3.79M | 602.00K | ||||
| Total Liabilities | 58.03M | 53.76M | 38.56M | 14.47M | 35.95M | 6.26M |
| Common Stock | 632.02M | 513.28M | 509.81M | 259.37M | 16.39M | 16.36M |
| Additional Paid-In Capital | 64.13M | 27.35M | 18.95M | 13.72M | 7.68M | 7.59M |
| Retained Earnings | -464.51M | -372.03M | -254.73M | -199.59M | -99.67M | -75.21M |
| Comprehensive Income & Other | -1.35M | -888.00K | -1.42M | -1.02M | -1.02M | -2.18M |
| Total Common Equity | 230.29M | 167.71M | 272.61M | 72.49M | -76.61M | -53.44M |
| Shareholders' Equity | 230.29M | 167.71M | 272.61M | 72.49M | -12.04M | 8.76M |
| Total Liabilities & Equity | 288.32M | 221.47M | 311.17M | 86.96M | 23.91M | 15.03M |
| Total Debt | 33.27M | 31.80M | 25.02M | 9.78M | 28.32M | 3.55M |
| Net Cash (Debt) | 233.05M | 161.94M | 213.31M | 71.74M | -7.88M | 7.46M |
| Net Cash Per Share | 3.61 | 3.17 | 5.65 | 103.58 | -12.04 | 2.09 |
| Filing Date Shares Outstanding | 67.02M | 66.98M | 50.98M | 23.20M | 3.89M | 3.56M |
| Total Common Shares Outstanding | 67.01M | 52.02M | 50.98M | 23.20M | 3.69M | 3.56M |
| Working Capital | 250.69M | 169.41M | 232.70M | 80.18M | 17.48M | 10.30M |
| Book Value Per Share | 3.44 | 3.22 | 5.35 | 3.12 | -20.77 | -15.00 |
| Tangible Book Value | 230.29M | 167.71M | 272.61M | 72.49M | -76.61M | -53.44M |
| Tangible Book Value Per Share | 3.44 | 3.22 | 5.35 | 3.12 | -20.77 | -15.00 |
| Machinery | 4.43M | 4.17M | 2.39M | 2.12M | 1.75M | 1.80M |
| Leasehold Improvements | 220.00K | 262.00K | 239.00K | 129.00K | 122.00K | 129.00K |
Cash flow statement
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -130.36M | -117.30M | -55.14M | -99.92M | -24.46M | -23.44M |
| Depreciation & Amortization | 718.00K | 509.00K | 323.00K | 175.00K | 238.00K | 272.00K |
| Other Amortization | 924.00K | |||||
| Loss (Gain) From Sale of Assets | 22.00K | |||||
| Loss (Gain) From Sale of Investments | -1.79M | -3.07M | -232.00K | |||
| Stock-Based Compensation | 17.36M | 9.65M | 5.32M | 3.45M | 116.00K | 435.00K |
| Other Operating Activities | 2.19M | 1.24M | 1.33M | 71.14M | 4.34M | 7.79M |
| Change in Accounts Payable | -179.00K | 4.94M | 474.00K | 373.00K | -197.00K | 110.00K |
| Change in Other Net Operating Assets | 8.87M | 5.39M | -2.39M | 117.00K | 2.23M | -1.44M |
| Operating Cash Flow | -103.31M | -99.24M | -48.28M | -24.74M | -17.59M | -15.98M |
| Capital Expenditures | -688.00K | -1.49M | -925.00K | -318.00K | -153.00K | -248.00K |
| Sale of Property, Plant & Equipment | 1.00K | |||||
| Investment in Securities | -31.35M | -23.65M | -125.03M | |||
| Investing Cash Flow | -32.04M | -25.14M | -125.95M | -318.00K | -153.00K | -247.00K |
| Long-Term Debt Issued | 22.50M | 38.00M | 29.40M | 8.03M | ||
| Long-Term Debt Repaid | -699.00K | -9.45M | -4.73M | -1.01M | -964.00K | |
| Net Debt Issued (Repaid) | 1.95M | -699.00K | 13.05M | 33.27M | 28.39M | 7.07M |
| Issuance of Common Stock | 151.79M | 2.22M | 266.25M | 56.94M | 12.00K | 14.00K |
| Other Financing Activities | -9.99M | -13.58M | -4.06M | -435.00K | -144.00K | |
| Financing Cash Flow | 143.75M | 1.52M | 265.72M | 86.15M | 27.97M | 22.52M |
| Foreign Exchange Rate Adjustments | 1.00K | 1.00K | 1.00K | 1.00K | -805.00K | 98.00K |
| Net Cash Flow | 8.40M | -122.85M | 91.48M | 61.09M | 9.42M | 6.39M |
| Free Cash Flow | -104.00M | -100.72M | -49.21M | -25.06M | -17.75M | -16.23M |
| Free Cash Flow Per Share | -1.61 | -1.97 | -1.30 | -36.18 | -27.09 | -4.56 |
| Levered Free Cash Flow | -60.85M | -60.38M | -32.23M | -16.07M | -10.75M | |
| Unlevered Free Cash Flow | -58.93M | -58.51M | -30.48M | -13.89M | -9.86M | |
| Cash Interest Paid | 2.30M | 2.29M | 1.93M | 615.00K | ||
| Change in Working Capital | 8.42M | 9.74M | 95.00K | -517.00K | 2.17M | -1.04M |
Ratios
Fiscal year November - October; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 97.17M | 369.09M | 451.12M | 343.05M | 160.50M | |
| Enterprise Value | -135.88M | 198.56M | 218.30M | 438.17M | ||
| Last Close Price | 1.45 | 7.21 | 8.85 | 21.70 | 10.15 | |
| PB Ratio | 0.42 | 2.20 | 1.66 | 4.73 | -13.33 | |
| P/TBV Ratio | 0.42 | 2.20 | 1.66 | 4.73 | ||
| Debt / Equity Ratio | 0.14 | 0.19 | 0.09 | 0.14 | -2.35 | 0.41 |
| Net Debt / Equity Ratio | -1.01 | -0.97 | -0.78 | -0.99 | -0.66 | -0.85 |
| Net Debt / EBITDA Ratio | 1.71 | 1.32 | 3.44 | 2.77 | -0.41 | 0.48 |
| Net Debt / FCF Ratio | 2.24 | 1.61 | 4.33 | 2.86 | -0.44 | 0.46 |
| Quick Ratio | 9.89 | 6.13 | 16.33 | 15.95 | 4.26 | 3.93 |
| Current Ratio | 10.21 | 6.30 | 16.87 | 16.25 | 4.42 | 4.20 |
| Return on Equity (ROE) | -60.50% | -53.28% | -31.96% | -330.60% | ||
| Return on Assets (ROA) | -31.99% | -28.90% | -19.56% | -29.38% | -62.37% | |
| Return on Capital Employed (ROCE) | -52.30% | -65.00% | -21.00% | -31.90% | -103.30% | -134.40% |
| Earnings Yield | -139.34% | -31.78% | -12.22% | -29.13% | -15.24% | |
| FCF Yield | -107.02% | -27.29% | -10.91% | -7.31% | -11.06% | |
| Buyback Yield / Dilution | -30.65% | -35.30% | -5,355.08% | -5.72% | 81.61% | -28.93% |